Tag: GLP-1 receptor agonists

A major review argues that the newly renamed polyendocrine metabolic ovarian syndrome is a lifelong systems-level disease driven by hypothalamic, ...

A Mount Sinai retrospective analysis suggests GLP-1 receptor agonists may reduce cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa.

A JAMA cross-sectional study quantifies how frequently commercially insured women in the United States begin GLP-1 receptor agonist prescriptions after ...

A new JAMA Perspective argues that GLP-1 therapies must be embedded in multimodal obesity care combining screening, early management, and ...

A new bibliometric analysis of 3,736 articles maps how GLP-1-based diabetes research exploded from 7 papers in 2004 to 589 ...

UTHealth Houston researchers have received a five-year, $4 million NIH grant to identify genetic markers and molecular mechanisms behind weight ...

A new review argues that fat stored within skeletal muscle could become a routine clinical biomarker of muscle health, linking ...

A major review details the bidirectional links between sleep disorders and obesity and how new weight-loss drugs are reshaping treatment.

A network meta-analysis of 29 randomized trials finds semaglutide best targets antipsychotic-related weight and blood sugar problems while metformin shows ...

A new meta-analysis of 23 randomized trials finds that SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists each ...